3507-17-3

Usage

Uses

Used in Organic Synthesis:
2-BROMO-6-CHLORO-BENZOTHIAZOLE is used as a synthetic intermediate for the preparation of various organic compounds. Its reactive bromo and chloro substituents allow for further functionalization, making it a versatile building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-BROMO-6-CHLORO-BENZOTHIAZOLE is used as a key component in the development of new drugs. Its unique structure and functional groups can be incorporated into drug molecules to enhance their therapeutic properties, such as potency, selectivity, and bioavailability.
Used in Materials Science:
2-BROMO-6-CHLORO-BENZOTHIAZOLE is utilized in materials science for the development of novel materials with specific properties. Its incorporation into polymers, coatings, or other materials can impart desirable characteristics, such as improved stability, enhanced performance, or tailored properties for specific applications.
For more detailed information regarding the physical properties, toxicity, and reactivity of 2-BROMO-6-CHLORO-BENZOTHIAZOLE, it is recommended to consult its Material Safety Data Sheet or refer to authoritative chemical databases.

InChI:InChI=1/C7H3BrClNS/c8-7-10-5-2-1-4(9)3-6(5)11-7/h1-3H

Upstream product

• 95-24-9 6-chloro-2-aminobenzothiazole 
• 7787-70-4 copper(I) bromide 

Downstream Products

• 51618-29-2 6-chloro-1,3-benzothiazole-2(3H)-thione 
• 441712-32-9 trans-4-[1-[[3-chloro-4-(6-chloro-2-benzothiazolyl)aminophenyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid 
• 441714-94-9 C₂₈H₃₀Cl₂FN₃O₄S 
• 441714-93-8 [3-chloro-4-(6-chloro-2-benzothiazolyl)aminophenyl]acetic acid 
• 1440509-65-8 C₁₅H₈ClNS 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6- benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

For the purpose of obtaining orally potent VLA-4 inhibitors, we have carried out structural modification of the (N′-phenylureido)phenyl group in compound 1, where the group was found to be attributed to poor pharmacokinetic profile in our previous research. Through modification, we have identified several compounds with both potent in vitro activity and improved oral exposure. In particular, compound 7e with 7-fluoro-2-(1-methyl-1H-indol-3- yl)-1,3-benzoxazolyl group as a novel replacement of the (N′-phenylureido) phenyl group significantly inhibited eosinophil infiltration into bronchoalveolar lavage fluid at 15 mg/kg in an Ascaris-antigen-induced murine bronchial inflammatory model, and its efficacy was comparable to that of the anti-mouse α4 antibody (R1-2).

Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)- thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors

4-(1,3-Benzothiazol-2-yl)thiophene-2-sulfonamide (4a) was found to be a moderately potent inhibitor of cyclin-dependent kinase 5 (cdk5) from a HTS screen. The synthesis and SAR around this hit is described. The X-ray coordinates of ligand 4a with cdk5 are also reported, showing an unusual binding mode to the hinge region via a water molecule.

New Compounds Useful for Treating CNS Disorders

The present invention provides new compounds of formula (I) as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

Substituted phenoxyalkanecarboxylic acid esters used to combat weeds in rice fields

Novel substituted phenoxyalkanecarboxylic acid esters of the formula STR1 in which R1 and R2, independently of one another, are a hydrogen atom, a halogen atom, a lower alkyl group or a nitro group, or R1 and R2, together with the benzene ring to which they are bonded, are a naphthalene ring, R3 and R4, independently of one another, are a hydrogen atom or a methyl group, n is 1 or 2, m is 0 or 1, X is an oxygen atom, a sulfur atom, a sulfonyl group or a group of the formula STR2 in which R6 is a lower alkyl group, R5 is a hydrogen atom or a halogen atom, and Y is an oxygen atom or a sulfur atom, and the use of the new compounds as herbicides.